These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 451317)
1. Kinetics of minimal residual disease. Salmon SE Recent Results Cancer Res; 1979; 67():1-15. PubMed ID: 451317 [No Abstract] [Full Text] [Related]
2. Relationship between tumor stem cell heterogeneity and responsiveness to chemotherapy. Skipper HE; Simpson-Herren L Important Adv Oncol; 1985; ():63-77. PubMed ID: 3870935 [No Abstract] [Full Text] [Related]
3. Implications of certain cell kinetic and biological parameters for preoperative chemotherapy. Hill BT Recent Results Cancer Res; 1986; 103():41-53. PubMed ID: 3526475 [No Abstract] [Full Text] [Related]
4. Combination chemotherapy--theory and practice. Capizzi RL; Keiser LW; Sartorelli AC Semin Oncol; 1977 Jun; 4(2):227-53. PubMed ID: 327555 [No Abstract] [Full Text] [Related]
5. Mathematic models of cell synchrony and drug scheduling. Valleron Aj Cancer Treat Rep; 1976 Dec; 60(12):1899-911. PubMed ID: 1026345 [No Abstract] [Full Text] [Related]
6. Single-agent chemotherapy of a solid murine tumor assayed by growth delay and cell survival. Begg AC; Fu KK; Kane LJ; Phillips TL Cancer Res; 1980 Jan; 40(1):145-54. PubMed ID: 7349894 [No Abstract] [Full Text] [Related]
7. A critical appraisal of the "human tumor stem-cell assay". Selby P; Buick RN; Tannock I N Engl J Med; 1983 Jan; 308(3):129-34. PubMed ID: 6336820 [No Abstract] [Full Text] [Related]
8. Proliferative character and growth modes of neoplastic disease as determinants of chemotherapeutic efficacy. Schenken LL Cancer Treat Rep; 1976 Dec; 60(12):1761-76. PubMed ID: 829040 [No Abstract] [Full Text] [Related]
9. Biology of residual breast cancer after therapy: a kinetic interpretation. Norton L Prog Clin Biol Res; 1990; 354A():109-32. PubMed ID: 2247484 [No Abstract] [Full Text] [Related]
10. Adjuvant chemotherapy: theoretical considerations and model studies. van Putten LM; de Ruiter J; van de Velde CJ; Mulder JH; Gerritsen AF Recent Results Cancer Res; 1979; 67():119-25. PubMed ID: 451320 [TBL] [Abstract][Full Text] [Related]
12. Comparative chemosensitivity of exponential- versus plateau-phase cells in both in vitro model systems. Twentyman PR Cancer Treat Rep; 1976 Dec; 60(12):1719-22. PubMed ID: 67890 [No Abstract] [Full Text] [Related]
13. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses. Frei E; Richardson P; Avigan D; Bunnell C; Wheeler C; Elias A Bone Marrow Transplant; 1999 Nov; 24(9):939-45. PubMed ID: 10556951 [TBL] [Abstract][Full Text] [Related]
14. Lethal and kinetic effects of peptichemio on cultured human lymphoma cells. Barlogie B; Drewinko B; Göhde W; Bodey GP Cancer Res; 1977 Aug; 37(8 Pt 1):2583-8. PubMed ID: 872086 [No Abstract] [Full Text] [Related]
15. Some variables in experimental tumor systems which complicate interpretation of data from in vivo kinetic and pharmacologic studies with anticancer drugs. Schabel FM; Simpson-Herren L Antibiot Chemother (1971); 1978; 23():113-27. PubMed ID: 348072 [No Abstract] [Full Text] [Related]
17. [Oncobiogram and its significance in the choice and efficacy of cytostatic therapy]. Savran VR Vopr Onkol; 1983; 29(3):106-13. PubMed ID: 6340347 [No Abstract] [Full Text] [Related]
18. Mathematical analysis of cancer chemotherapy: the effects of chemotherapeutic agents on the cell cycle traverse. Chuang SN; Soong TT Bull Math Biol; 1978; 40(4):499-512. PubMed ID: 678695 [No Abstract] [Full Text] [Related]
19. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Leung PY; Miyashita K; Young M; Tsao CS Anticancer Res; 1993; 13(2):475-80. PubMed ID: 8517665 [TBL] [Abstract][Full Text] [Related]
20. Clinical concepts derived from animal chemotherapy studies. Goldin A; Schabel FM Cancer Treat Rep; 1981; 65 Suppl 3():11-9. PubMed ID: 7049366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]